Sacchetto L, Zanetti R, Comber H, Bouchardy C, Brewster DH, Broganelli P, Chirlaque MD, Coza D, Galceran J, Gavin A, et al: Trends in incidence of thick, thin and in situ melanoma in Europe. Eur J Cancer. 92:108–118. 2018. View Article : Google Scholar : PubMed/NCBI

Rabbie R, Ferguson P, Molina-Aguilar C, Adams DJ and Robles-Espinoza CD: Melanoma subtypes: Genomic profiles, prognostic molecular markers and therapeutic possibilities. J Pathol. 247:539–551. 2019. View Article : Google Scholar :

Lorentzen HF: Targeted therapy for malignant melanoma. Curr Opin Pharmacol. 46:116–121. 2019. View Article : Google Scholar : PubMed/NCBI

Paget S: The distribution of secondary growths in cancer of the breast. Lancet. 133:571–573. 1889. View Article : Google Scholar

Faries MB, Thompson JF, Cochran AJ, Andtbacka RH, Mozzillo N, Zager JS, Jahkola T, Bowles TL, Testori A, Beitsch PD, et al: Completion dissection or observation for sentinel-node metastasis in melanoma. N Engl J Med. 376:2211–2222. 2017. View Article : Google Scholar : PubMed/NCBI

Nathanson SD: Insights into the mechanisms of lymph node metastasis. Cancer. 98:413–423. 2003. View Article : Google Scholar : PubMed/NCBI

Barth A, Wanek LA and Morton DL: Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg. 181:193–201. 1995.PubMed/NCBI

Damsky WE Jr and Bosenberg M: Mouse melanoma models and cell lines. Pigment Cell Melanoma Res. 23:853–859. 2010. View Article : Google Scholar : PubMed/NCBI

Abdel-Ghany M, Cheng HC, Elble RC and Pauli BU: The breast cancer ß 4 integrin and endothelial human CLCA2 mediate lung metastasis. J Biol Chem. 276:25438–25446. 2001. View Article : Google Scholar : PubMed/NCBI

Tawbi HA, Boutros C, Kok D, Robert C and McArthur G: New era in the management of melanoma brain metastases. Am Soc Clin Oncol Educ Book. 38:741–750. 2018. View Article : Google Scholar : PubMed/NCBI

Menter DG, Herrmann JL and Nicolson GL: The role of trophic factors and autocrine/paracrine growth factors in brain metastasis. Clin Exp Metastasis. 13:67–88. 1995. View Article : Google Scholar : PubMed/NCBI

Balch CM, Houghton AN, Sober AJ and Soong S: Cutaneous Melanoma, 4th Edition. Dermatologic Surg. 31:1715. 2005. View Article : Google Scholar

Murakami T, Cardones AR and Hwang ST: Chemokine receptors and melanoma metastasis. J Dermatol Sci. 36:71–78. 2004. View Article : Google Scholar : PubMed/NCBI

Martinez-Rodriguez M, Thompson AK and Monteagudo C: High CCL27 immunoreactivity in 'supratumoral' epidermis correlates with better prognosis in patients with cutaneous malignant melanoma. J Clin Pathol. 70:15–19. 2017. View Article : Google Scholar

Ben-Baruch A: Organ selectivity in metastasis: Regulation by chemokines and their receptors. Clin Exp Metastasis. 25:345–356. 2008. View Article : Google Scholar

Marcoval J, Ferreres JR, Martrn C, Gomez S, Penrn RM, Ochoa de Olza M and Fabra À: Patterns of Visceral Metastasis in Cutaneous Melanoma: A Descriptive Study. Actas Dermosifiliog. 104:593–597. 2013. View Article : Google Scholar

Adler NR, Wolfe R, Kelly JW, Haydon A, McArthur GA, McLean CA and Mar VJ: Tumour mutation status and sites of metastasis in patients with cutaneous melanoma. Br J Cancer. 117:1026–1035. 2017. View Article : Google Scholar : PubMed/NCBI

Holt JB, Sangueza OP, Levine EA, Shen P, Bergman S, Geisinger KR and Creager AJ: Nodal melanocytic nevi in sentinel lymph nodes. Correlation with melanoma-associated cutaneous nevi. Am J Clin Pathol. 121:58–63. 2004. View Article : Google Scholar : PubMed/NCBI

Ji Y, Hao H, Reynolds K, McMahon M and Zhou CJ: Wnt signaling in neural crest ontogenesis and oncogenesis. Cells. 8:11732019. View Article : Google Scholar :

Lim J, Thiery JP, Kassem Y, Kalcheim C, Moens CB, Burden SJ and Granato M: Epithelial-mesenchymal transitions: Insights from development. Development. 139:3471–3486. 2012. View Article : Google Scholar : PubMed/NCBI

Mayor R and Theveneau E: The neural crest. Development. 140:2247–2251. 2013. View Article : Google Scholar : PubMed/NCBI

Hall BK: The neural crest and neural crest cells: Discovery and significance for theories of embryonic organization. J Biosci. 33:781–793. 2008. View Article : Google Scholar

Mort RL, Jackson IJ and Patton EE: The melanocyte lineage in development and disease. Development. 142:620–632. 2015. View Article : Google Scholar : PubMed/NCBI

Duband JL, Monier F, Delannet M and Newgreen D: Epithelium-mesenchyme transition during neural crest development. Acta Anat (Basel). 154:63–78. 1995. View Article : Google Scholar

Vega-Lopez GA, Cerrizuela S and Aybar MJ: Trunk neural crest cells: Formation, migration and beyond. Int J Dev Biol. 61:5–15. 2017. View Article : Google Scholar : PubMed/NCBI

Larribère L and Utikal J: Stem cell-derived models of neural crest are essential to understand melanoma progression and therapy resistance. Front Mol Neurosci. 12:1112019. View Article : Google Scholar : PubMed/NCBI

Gallik KL, Treffy RW, Nacke LM, Ahsan K, Rocha M, Green-Saxena A and Saxena A: Neural crest and cancer: Divergent travelers on similar paths. Mech Dev. 148:89–99. 2017. View Article : Google Scholar : PubMed/NCBI

Sieber-Blum M and Grim M: The adult hair follicle: Cradle for pluripotent neural crest stem cells. Birth Defects Res C Embryo Today. 72:162–172. 2004. View Article : Google Scholar : PubMed/NCBI

Person F, Wilczak W, Hube-Magg C, Burdelski C, Moller-Koop C, Simon R, Noriega M, Sauter G, Steurer S, Burdak-Rothkamm S, et al: Prevalence of pIII-tubulin (TUBB3) expression in human normal tissues and cancers. Tumour Biol. 39:10104283177121662017. View Article : Google Scholar

Stasiak M, Boncela J, Perreau C, Karamanou K, Chatron-Colliet A, Proult I, Przygodzka P, Chakravarti S, Maquart FX, Kowalska MA, et al: Lumican inhibits SNAIL-induced melanoma cell migration specifically by blocking MMP-14 activity. PLoS One. 11:e01502262016. View Article : Google Scholar : PubMed/NCBI

Yang X, Liang R, Liu C, Liu JA, Cheung MPL, Liu X, Man OY, Guan XY, Lung HL and Cheung M: SOX9 is a dose-dependent metastatic fate determinant in melanoma. J Exp Clin Cancer Res. 38:172019. View Article : Google Scholar : PubMed/NCBI

Lee H, Torres FX, McLean SA, Chen R and Lee MW: Immunophenotypic heterogeneity of primary sinonasal melanoma with aberrant expression of neuroendocrine markers and calponin. Appl Immunohistochem Mol Morphol. 19:48–53. 2011. View Article : Google Scholar

Tudrej KB, Czepielewska E and Kozlowska-Wojciechowska M: SOX10-MITF pathway activity in melanoma cells. Arch Med Sci. 13:1493–1503. 2017. View Article : Google Scholar : PubMed/NCBI

Iwakami Y, Yokoyama S, Watanabe K and Hayakawa Y: STAM-binding protein regulates melanoma metastasis through SLUG stabilization. Biochem Biophys Res Commun. 507:484–488. 2018. View Article : Google Scholar : PubMed/NCBI

Goding CR and Arnheiter H: MITF-the first 25 years. Genes Dev. 33:983–1007. 2019. View Article : Google Scholar : PubMed/NCBI

Campbell K, Kumarapeli AR, Gokden N, Cox RM, Hutchins L and Gardner JM: Metastatic melanoma with dedifferentiation and extensive rhabdomyosarcomatous heterologous component. J Cutan Pathol. 45:360–364. 2018. View Article : Google Scholar : PubMed/NCBI

Krejci E and Grim M: Isolation and characterization of neural crest stem cells from adult human hair follicles. Folia Biol (Praha). 56:149–157. 2010.

Marzagalli M, Raimondi M, Fontana F, Montagnani Marelli M, Moretti RM and Limonta P: Cellular and molecular biology of cancer stem cells in melanoma: Possible therapeutic implications. Semin Cancer Biol. 59:221–235. 2019. View Article : Google Scholar : PubMed/NCBI

Kasemeier-Kulesa JC, Teddy JM, Postovit LM, Seftor EA, Seftor REB, Hendrix MJC and Kulesa PM: Reprogramming multipotent tumor cells with the embryonic neural crest microenvironment. Dev Dyn. 237:2657–2666. 2008. View Article : Google Scholar : PubMed/NCBI

Kaufman CK, Mosimann C, Fan ZP, Yang S, Thomas AJ, Ablain J, Tan JL, Fogley RD, van Rooijen E, Hagedorn EJ, et al: A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science. 351:aad21972016. View Article : Google Scholar : PubMed/NCBI

Agnoletto C, Corrà F, Minotti L, Baldassari F, Crudele F, Cook WJJ, Di Leva G, d'Adamo AP, Gasparini P and Volinia S: Heterogeneity in circulating tumor cells: The relevance of the stem-cell subset. Cancers (Basel). 11:112019. View Article : Google Scholar

Gkountela S and Aceto N: Stem-like features of cancer cells on their way to metastasis. Biol Direct. 11:332016. View Article : Google Scholar : PubMed/NCBI

Empringham B, Chiang KY and Krueger J: Collection of hematopoietic stem cells and immune effector cells in small children. Transfus Apheresis Sci. 57:614–618. 2018. View Article : Google Scholar

Feehan J, Nurgali K, Apostolopoulos V, Al Saedi A and Duque G: Circulating osteogenic precursor cells: Building bone from blood. EBioMedicine. 39:603–611. 2019. View Article : Google Scholar :

Ratajczak MZ, Bujko K, Mack A, Kucia M and Ratajczak J: Cancer from the perspective of stem cells and misappropriated tissue regeneration mechanisms. Leukemia. 32:2519–2526. 2018. View Article : Google Scholar : PubMed/NCBI

Lacina L, Plzak J, Kodet O, Szabo P, Chovanec M, Dvorankova B and Smetana K Jr: Cancer microenvironment: What can we learn from the stem cell niche. Int J Mol Sci. 16:24094–24110. 2015. View Article : Google Scholar : PubMed/NCBI

Hill BS, Pelagalli A, Passaro N and Zannetti A: Tumor-educated mesenchymal stem cells promote pro-metastatic phenotype. Oncotarget. 8:73296–73311. 2017. View Article : Google Scholar : PubMed/NCBI

Plzak J, Boucek J, Bandurova V, Kolar M, Hradilova M, Szabo P, Lacina L, Chovanec M and Smetana K Jr: The head and neck squamous cell carcinoma microenvironment as a potential target for cancer therapy. Cancers (Basel). 11:112019. View Article : Google Scholar

Lacina L, Kodet O, Dvorankova B, Szabo P and Smetana K Jr: Ecology of melanoma cell. Histol Histopathol. 33:247–254. 2018.

Preisner F, Leimer U, Sandmann S, Zoernig I, Germann G and Koellensperger E: Impact of human adipose tissue-derived stem cells on malignant melanoma cells in an in vitro co-culture model. Stem Cell Rev Rep. 14:125–140. 2018. View Article : Google Scholar

Dvorankova B, Smetana K Jr, Rihova B, Kucera J, Mateu R and Szabo P: Cancer-associated fibroblasts are not formed from cancer cells by epithelial-to-mesenchymal transition in nu/nu mice. Histochem Cell Biol. 143:463–469. 2015. View Article : Google Scholar

Inada M, Takita M, Yokoyama S, Watanabe K, Tominari T, Matsumoto C, Hirata M, Maru Y, Maruyama T, Sugimoto Y, et al: Direct melanoma cell contact induces stromal cell autocrine prostaglandin E2-EP4 receptor signaling that drives tumor growth, angiogenesis, and metastasis. J Biol Chem. 290:29781–29793. 2015. View Article : Google Scholar : PubMed/NCBI

Ziani L, Safta-Saadoun TB, Gourbeix J, Cavalcanti A, Robert C, Favre G, Chouaib S and Thiery J: Melanoma-associated fibroblasts decrease tumor cell susceptibility to NK cell-mediated killing through matrix-metalloproteinases secretion. Oncotarget. 8:19780–19794. 2017. View Article : Google Scholar : PubMed/NCBI

Kodet O, Lacina L, Krejci E, Dvorankova B, Grim M, Stork J, Kodetova D, Vlcek C, Sachova J, Kolar M, et al: Melanoma cells influence the differentiation pattern of human epidermal keratinocytes. Mol Cancer. 14:12015. View Article : Google Scholar : PubMed/NCBI

Van Kilsdonk JWJ, Bergers M, Van Kempen LCLT, Schalkwijk J and Swart GWM: Keratinocytes drive melanoma invasion in a reconstructed skin model. Melanoma Res. 20:372–380. 2010.PubMed/NCBI

Ciolczyk-Wierzbicka D and Laidler P: The inhibition of invasion of human melanoma cells through N-cadherin knock-down. Med Oncol. 35:422018. View Article : Google Scholar : PubMed/NCBI

Chung H, Jung H, Jho EH, Multhaupt HAB, Couchman JR and Oh ES: Keratinocytes negatively regulate the N-cadherin levels of melanoma cells via contact-mediated calcium regulation. Biochem Biophys Res Commun. 503:615–620. 2018. View Article : Google Scholar : PubMed/NCBI

Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Heino J and Pyrhonen S: Integrin chains |31 and alphav as prognostic factors in human metastatic melanoma. Melanoma Res. 14:29–37. 2004. View Article : Google Scholar : PubMed/NCBI

Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry D IV, Schuchter L, Van Belle TJ, Albelda S, Tahin P, Herlyn M, et al: Progression-related expression of |33 integrin in melanomas and nevi. Hum Pathol. 30:562–567. 1999. View Article : Google Scholar : PubMed/NCBI

Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T and Herlyn M: Function and regulation of melanoma-stromal fibroblast interactions: When seeds meet soil. Oncogene. 22:3162–3171. 2003. View Article : Google Scholar : PubMed/NCBI

Brandner JM and Haass NK: Melanoma's connections to the tumour microenvironment. Pathology. 45:443–452. 2013. View Article : Google Scholar : PubMed/NCBI

Peitsch WK, Doerflinger Y, Fischer-Colbrie R, Huck V, Bauer AT, Utikal J, Goerdt S and Schneider SW: Desmoglein 2 depletion leads to increased migration and upregulation of the chemoattractant secretoneurin in melanoma cells. PLoS One. 9:e894912014. View Article : Google Scholar : PubMed/NCBI

Tan LY, Mintoff C, Johan MZ, Ebert BW, Fedele C, Zhang YF, Szeto P, Sheppard KE, McArthur GA, Foster-Smith E, et al: Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget. 7:46492–46508. 2016. View Article : Google Scholar : PubMed/NCBI

Klemke M, Weschenfelder T, Konstandin MH and Samstag Y: High affinity interaction of integrin a4pi (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. J Cell Physiol. 212:368–374. 2007. View Article : Google Scholar : PubMed/NCBI

Lacaria L, Lange JR, Goldmann WH, Rico F and Alonso JL: av|33 integrin expression increases elasticity in human melanoma cells. Biochem Biophys Res Commun. 525:836–840. 2020. View Article : Google Scholar : PubMed/NCBI

Bedogni B: Notch signaling in melanoma: Interacting pathways and stromal influences that enhance Notch targeting. Pigment Cell Melanoma Res. 27:162–168. 2014. View Article : Google Scholar

Jobe NP, Rosel D, Dvorankova B, Kodet O, Lacina L, Mateu R, Smetana K and Brabek J: Simultaneous blocking of IL-6 and IL-8 is sufficient to fully inhibit CAF-induced human melanoma cell invasiveness. Histochem Cell Biol. 146:205–217. 2016. View Article : Google Scholar : PubMed/NCBI

Jobe NP, Zivicova V, Mifkova A, Rosel D, Dvorankova B, Kodet O, Strnad H, Kolar M, Sedo A, Smetana K Jr, et al: Fibroblasts potentiate melanoma cells in vitro invasiveness induced by UV-irradiated keratinocytes. Histochem Cell Biol. 149:503–516. 2018. View Article : Google Scholar : PubMed/NCBI

Strnadova K, Sandera V, Dvorankova B, Kodet O, Duskova M, Smetana K and Lacina L: Skin aging: The dermal perspective. Clin Dermatol. 37:326–335. 2019. View Article : Google Scholar : PubMed/NCBI

Payne AS and Cornelius LA: The role of chemokines in melanoma tumor growth and metastasis. J Invest Dermatol. 118:915–922. 2002. View Article : Google Scholar : PubMed/NCBI

Gebhardt C, Averbeck M, Viertel A, Kauer F, Saalbach A, Anderegg U and Simon JC: Ultraviolet-B irradiation enhances melanoma cell motility via induction of autocrine interleukin 8 secretion. Exp Dermatol. 16:636–643. 2007. View Article : Google Scholar : PubMed/NCBI

Araki K, Shimura T, Yajima T, Tsutsumi S, Suzuki H, Okada K, Kobayashi T, Raz A and Kuwano H: Phosphoglucose isomerase/autocrine motility factor promotes melanoma cell migration through ERK activation dependent on autocrine production of interleukin-8. J Biol Chem. 284:32305–32311. 2009. View Article : Google Scholar : PubMed/NCBI

Kemp DM, Pidich A, Larijani M, Jonas R, Lash E, Sato T, Terai M, De Pizzol M, Allegretti M, Igoucheva O, et al: Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment. Oncotarget. 8:14428–14442. 2017. View Article : Google Scholar : PubMed/NCBI

Brennecke S, Deichmann M, Naeher H and Kurzen H: Decline in angiogenic factors, such as interleukin-8, indicates response to chemotherapy of metastatic melanoma. Melanoma Res. 15:515–522. 2005. View Article : Google Scholar : PubMed/NCBI

Gabellini C, Trisciuoglio D, Desideri M, Candiloro A, Ragazzoni Y, Orlandi A, Zupi G and Del Bufalo D: Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer. 45:2618–2627. 2009. View Article : Google Scholar : PubMed/NCBI

Nürnberg W, Tobias D, Otto F, Henz BM and Schadendorf D: Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol. 189:546–551. 1999. View Article : Google Scholar

Ortega-Bernal D, La Rosa CHG, Arechaga-Ocampo E, Alvarez-Avitia MA, Moreno NS and Rangel-Escareno C: A meta-analysis of transcriptome datasets characterizes malignant transformation from melanocytes and nevi to melanoma. Oncol Lett. 16:1899–1911. 2018.PubMed/NCBI

Adamski V, Mentlein R, Lucius R, Synowitz M, Held-Feindt J and Hattermann K: The chemokine receptor CXCR6 evokes reverse signaling via the transmembrane chemokine CXCL16. Int J Mol Sci. 18:182017. View Article : Google Scholar

da Silva WC, Oshiro TM, de Sa DC, Franco DDGS, Festa Neto C and Pontillo A: Genotyping and differential expression analysis of inflammasome genes in sporadic malignant melanoma reveal novel contribution of CARD8, IL1B and IL18 in melanoma susceptibility and progression. Cancer Genet. 209:474–480. 2016. View Article : Google Scholar : PubMed/NCBI

Lacina L, Brabek J, Kral V, Kodet O and Smetana K Jr: Interleukin-6: A molecule with complex biological impact in cancer. Histol Histopathol. 34:125–136. 2019.

Armstrong CA, Murray N, Kennedy M, Koppula SV, Tara D and Ansel JC: Melanoma-derived interleukin 6 inhibits in vivo melanoma growth. J Invest Dermatol. 102:278–284. 1994. View Article : Google Scholar : PubMed/NCBI

Lu C and Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol. 120:1281–1288. 1993. View Article : Google Scholar : PubMed/NCBI

Elias EG, Hasskamp JH and Sharma BK: Cytokines and growth factors expressed by human cutaneous melanoma. Cancers (Basel). 2:794–808. 2010. View Article : Google Scholar

Linnskog R, Jönsson G, Axelsson L, Prasad CP and Andersson T: Interleukin-6 drives melanoma cell motility through p38a-MAPK-dependent up-regulation of WNT5A expression. Mol Oncol. 8:1365–1378. 2014. View Article : Google Scholar : PubMed/NCBI

Karst AM, Gao K, Nelson CC and Li G: Nuclear factor kappa B subunit p50 promotes melanoma angiogenesis by upregulating interleukin-6 expression. Int J Cancer. 124:494–501. 2009. View Article : Google Scholar

Nagai H, Oniki S, Fujiwara S, Xu M, Mizoguchi I, Yoshimoto T and Nishigori C: Antitumor activities of interleukin-27 on melanoma. Endocr Metab Immune Disord Drug Targets. 10:41–46. 2010. View Article : Google Scholar

Shinozaki Y, Wang S, Miyazaki Y, Miyazaki K, Yamada H, Yoshikai Y, Hara H and Yoshida H: Tumor-specific cytotoxic T cell generation and dendritic cell function are differentially regulated by interleukin 27 during development of anti-tumor immunity. Int J Cancer. 124:1372–1378. 2009. View Article : Google Scholar

Chiba Y, Mizoguchi I, Mitobe K, Higuchi K, Nagai H, Nishigori C, Mizuguchi J and Yoshimoto T: IL-27 enhances the expression of TRAIL and TLR3 in human melanomas and inhibits their tumor growth in cooperation with a TLR3 agonist poly(I:C) partly in a TRAIL-dependent manner. PLoS One. 8:e761592013. View Article : Google Scholar : PubMed/NCBI

Bisevac JP, Stanojevic I, Mijuskovic Z, Banovic T, Djukic M and Vojvodic D: High interleukin 27 production is associated with early clinical stage and localized disease in patients with melanoma. J Med Biochem. 35:443–450. 2016. View Article : Google Scholar

Onoue K, Kusubashi H, Sato Y, Wakitani S and Takagi M: Quantitative correlation between production rate of melanoma inhibitory activity and aggrecan gene expression level during differentiation from mesenchymal stem cells to chondrocytes and redifferentiation of chondrocytes. J Biosci Bioeng. 111:594–596. 2011. View Article : Google Scholar : PubMed/NCBI

Decarlo K, Yang S, Emley A, Wajapeyee N, Green M and Mahalingam M: Oncogenic BRAF-positive dysplastic nevi and the tumor suppressor IGFBP7 - challenging the concept of dysplastic nevi as precursor lesions? Hum Pathol. 41:886–894. 2010. View Article : Google Scholar : PubMed/NCBI

Yotsumoto F, Yagi H, Suzuki SO, Oki E, Tsujioka H, Hachisuga T, Sonoda K, Kawarabayashi T, Mekada E and Miyamoto S: Validation of HB-EGF and amphiregulin as targets for human cancer therapy. Biochem Biophys Res Commun. 365:555–561. 2008. View Article : Google Scholar

Marchetti D and Nicolson GL: Neurotrophin stimulation of human melanoma cell invasion: Selected enhancement of heparanase activity and heparanase degradation of specific heparan sulfate subpopulations. Adv Enzyme Regul. 37:111–134. 1997. View Article : Google Scholar : PubMed/NCBI

Antunes LCM, Cartell A, de Farias CB, Bakos RM, Roesler R and Schwartsmann G: Tropomyosin-related kinase receptor and neurotrophin expression in cutaneous melanoma is associated with a poor prognosis and decreased survival. Oncology. 97:26–37. 2019. View Article : Google Scholar : PubMed/NCBI

Li JR, Wang JQ, Gong Q, Fang RH and Guo YL: MicroRNA-328 inhibits proliferation of human melanoma cells by targeting TGFp2. Asian Pac J Cancer Prev. 16:1575–1579. 2015. View Article : Google Scholar

Hutchenreuther J, Vincent K, Norley C, Racanelli M, Gruber SB, Johnson TM, Fullen DR, Raskin L, Perbal B, Holdsworth DW, et al: Activation of cancer-associated fibroblasts is required for tumor neovascularization in a murine model of melanoma. Matrix Biol. 74:52–61. 2018. View Article : Google Scholar : PubMed/NCBI

Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI

Capparelli C, Rosenbaum S, Berger AC and Aplin AE: Fibroblast-derived neuregulin 1 promotes compensatory ErbB3 receptor signaling in mutant BRAF melanoma. J Biol Chem. 290:24267–24277. 2015. View Article : Google Scholar : PubMed/NCBI

Ruivo CF, Adem B, Silva M and Melo SA: The biology of cancer exosomes: Insights and new perspectives. Cancer Res. 77:6480–6488. 2017. View Article : Google Scholar : PubMed/NCBI

Hood JL: Melanoma exosome induction of endothelial cell GM-CSF in pre-metastatic lymph nodes may result in different M1 and M2 macrophage mediated angiogenic processes. Med Hypotheses. 94:118–122. 2016. View Article : Google Scholar : PubMed/NCBI

Xiao D, Barry S, Kmetz D, Egger M, Pan J, Rai SN, Qu J, McMasters KM and Hao H: Melanoma cell-derived exosomes promote epithelial-mesenchymal transition in primary melanocytes through paracrine/autocrine signaling in the tumor microenvironment. Cancer Lett. 376:318–327. 2016. View Article : Google Scholar : PubMed/NCBI

Gowda R, Robertson BM, Iyer S, Barry J, Dinavahi SS and Robertson GP: The role of exosomes in metastasis and progression of melanoma. Cancer Treat Rev. 85:1019752020. View Article : Google Scholar : PubMed/NCBI

Gajos-Michniewicz A and Czyz M: Role of mirnas in melanoma metastasis. Cancers (Basel). 11:112019. View Article : Google Scholar

Clayton A, Mitchell JP, Court J, Mason MD and Tabi Z: Human tumor-derived exosomes selectively impair lymphocyte responses to interleukin-2. Cancer Res. 67:7458–7466. 2007. View Article : Google Scholar : PubMed/NCBI

Gerloff D, Lützkendorf J, Moritz RKC, Wersig T, Mader K, Müller LP and Sunderkotter C: Melanoma-derived exosomal mir-125b-5p educates tumor associated macrophages (TAMs) by targeting lysosomal acid lipase A (LIPA). Cancers (Basel). 12:122020. View Article : Google Scholar

Bardi GT, Smith MA and Hood JL: Melanoma exosomes promote mixed M1 and M2 macrophage polarization. Cytokine. 105:63–72. 2018. View Article : Google Scholar : PubMed/NCBI

Gershenwald JE and Scolyer RA: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol. 25:2105–2110. 2018. View Article : Google Scholar : PubMed/NCBI

Michielin O, van Akkooi ACJ, Ascierto PA, Dummer R and Keilholz U; ESMO Guidelines Committee: Electronic address: simpleclinicalguidelines@esmo.org: Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 30:1884–1901. 2019. View Article : Google Scholar : PubMed/NCBI

Riechers A and Bosserhoff AK: Melanoma inhibitory activity in melanoma diagnostics and therapy - a small protein is looming large. Exp Dermatol. 23:12–14. 2014. View Article : Google Scholar : PubMed/NCBI

Forgber M, Trefzer U, Sterry W and Walden P: Proteome serological determination of tumor-associated antigens in melanoma. PLoS One. 4:e51992009. View Article : Google Scholar : PubMed/NCBI

Muqaku B, Eisinger M, Meier SM, Tahir A, Pukrop T, Haferkamp S, Slany A, Reichle A and Gerner C: Multi-omics analysis of serum samples demonstrates reprogramming of organ functions via systemic calcium mobilization and platelet activation in metastatic melanoma. Mol Cell Proteomics. 16:86–99. 2017. View Article : Google Scholar :

Weber JS, Sznol M, Sullivan RJ, Blackmon S, Boland G, Kluger HM, Halaban R, Bacchiocchi A, Ascierto PA, Capone M, et al: A serum protein signature associated with outcome after anti-PD-1 therapy in metastatic melanoma. Cancer Immunol Res. 6:79–86. 2018. View Article : Google Scholar

Hoejberg L, Bastholt L, Johansen JS, Christensen IJ, Gehl J and Schmidt H: Serum interleukin-6 as a prognostic biomarker in patients with metastatic melanoma. Melanoma Res. 22:287–293. 2012. View Article : Google Scholar : PubMed/NCBI

Correa D, Somoza RA, Lin P, Schiemann WP and Caplan AI: Mesenchymal stem cells regulate melanoma cancer cells extravasation to bone and liver at their perivascular niche. Int J Cancer. 138:417–427. 2016. View Article : Google Scholar :

Gandalovicova A, Rosel D, Fernandes M, Vesely P, Heneberg P, Cermak V, Petruzelka L, Kumar S, Sanz-Moreno V and Brabek J: Migrastatics-anti-metastatic and anti-invasion Drugs: Promises and challenges. Trends Cancer. 3:391–406. 2017. View Article : Google Scholar : PubMed/NCBI

Herman H, Fazakas C, Hasko J, Molnar K, Mészaros A, Nyul-Toth A, Szabo G, Erdélyi F, Ardelean A, Hermenean A, et al: Paracellular and transcellular migration of metastatic cells through the cerebral endothelium. J Cell Mol Med. 23:2619–2631. 2019. View Article : Google Scholar : PubMed/NCBI

Kucera R, Topolcan O, Treskova I, Kinkorova J, Windrichova J, Fuchsova R, Svobodova S, Treska V, Babuska V, Novak J, et al: Evaluation of IL-2, IL-6, IL-8 and IL-10 in malignant melanoma diagnostics. Anticancer Res. 35:3537–3541. 2015.PubMed/NCBI

Sanmamed MF, Carranza-Rua O, Alfaro C, Onate C, Martin-Algarra S, Perez G, Landazuri SF, Gonzalez A, Gross S, Rodriguez I, et al: Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res. 20:5697–5707. 2014. View Article : Google Scholar : PubMed/NCBI

Kucera J, Strnadova K, Dvorankova B, Lacina L, Krajsova I, Stork J, Kovarova H, Skalmkova HK, Vodicka P, Motlik J, et al: Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study. Oncol Rep. 42:1793–1804. 2019.PubMed/NCBI

Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, Laurent R, Humbert P and Aubin F: Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol. 152:685–689. 2005. View Article : Google Scholar : PubMed/NCBI

Ugurel S, Rappl G, Tilgen W and Reinhold U: Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol. 19:577–583. 2001. View Article : Google Scholar : PubMed/NCBI

Krasagakis K, Tholke D, Farthmann B, Eberle J, Mansmann U and Orfanos CE: Elevated plasma levels of transforming growth factor (TGF)-pi and TGF-|32 in patients with disseminated malignant melanoma. Br J Cancer. 77:1492–1494. 1998. View Article : Google Scholar : PubMed/NCBI

Tuccitto A, Tazzari M, Beretta V, Rini F, Miranda C, Greco A, Santinami M, Patuzzo R, Vergani B, Villa A, et al: Immunomodulatory factors control the fate of melanoma tumor initiating cells. Stem Cells. 34:2449–2460. 2016. View Article : Google Scholar : PubMed/NCBI

Tung KH, Ernstoff MS, Allen C and Shu S: A Review of exosomes and their role in the tumor microenvironment and host-tumor 'macroenvironment'. J Immunol Sci. 3:4–8. 2019. View Article : Google Scholar :

Shu S, Yang Y, Allen CL, Maguire O, Minderman H, Sen A, Ciesielski MJ, Collins KA, Bush PJ, Singh P, et al: Metabolic reprogramming of stromal fibroblasts by melanoma exosome microRNA favours a pre-metastatic microenvironment. Sci Rep. 8:129052018. View Article : Google Scholar : PubMed/NCBI

Kodet O, Dvorankova B, Bendlova B, Sykorova V, Krajsova I, Stork J, Kucera J, Szabo P, Strnad H, Kolar M, et al: Microenvironment driven resistance to B Raf inhibition in a melanoma patient is accompanied by broad changes of gene methylation and expression in distal fibroblasts. Int J Mol Med. 41:2687–2703. 2018.PubMed/NCBI

Jouve N, Bachelier R, Despoix N, Blin MG, Matinzadeh MK, Poitevin S, Aurrand-Lions M, Fallague K, Bardin N, Blot-Chabaud M, et al: CD146 mediates vEGF-induced melanoma cell extravasation through FAK activation. Int J Cancer. 137:50–60. 2015. View Article : Google Scholar

Hamilla SM, Stroka KM and Aranda-Espinoza H: VE-cadherin-independent cancer cell incorporation into the vascular endothelium precedes transmigration. PLoS One. 9:e1097482014. View Article : Google Scholar : PubMed/NCBI

Kim KJ, Kwon SH, Yun JH, Jeong HS, Kim HR, Lee EH, Ye SK and Cho CH: STAT3 activation in endothelial cells is important for tumor metastasis via increased cell adhesion molecule expression. Oncogene. 36:5445–5459. 2017. View Article : Google Scholar : PubMed/NCBI

Borgenström M, Wärri A, Hiilesvuo K, Käkönen R, Käkönen S, Nissinen L, Pihlavisto M, Marjamäki A, Vlodavsky I, Naggi A, et al: O-sulfated bacterial polysaccharides with low anticoagulant activity inhibit metastasis. Semin Thromb Hemost. 33:547–556. 2007. View Article : Google Scholar : PubMed/NCBI

Dange MC, Srinivasan N, More SK, Bane SM, Upadhya A, Ingle AD, Gude RP, Mukhopadhyaya R and Kalraiya RD: Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells. Clin Exp Metastasis. 31:661–673. 2014. View Article : Google Scholar : PubMed/NCBI

Desch A, Strozyk EA, Bauer AT, Huck V, Niemeyer V, Wieland T and Schneider SW: Highly invasive melanoma cells activate the vascular endothelium via an MMP-2/integrin αvβ5-induced secretion of VEGF-A. Am J Pathol. 181:693–705. 2012. View Article : Google Scholar : PubMed/NCBI

Tsukamoto H, Fujieda K, Miyashita A, Fukushima S, Ikeda T, Kubo Y, Senju S, Ihn H, Nishimura Y and Oshiumi H: Combined blockade of IL6 and PD-1/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 78:5011–5022. 2018. View Article : Google Scholar : PubMed/NCBI

Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, Morley JE, Strasser F, Landmesser U, Coats AJS, et al: Orphan disease status of cancer cachexia in the USA and in the European Union: A systematic review. J Cachexia Sarcopenia Muscle. 10:22–34. 2019. View Article : Google Scholar : PubMed/NCBI

Loumaye A and Thissen JP: Biomarkers of cancer cachexia. Clin Biochem. 50:1281–1288. 2017. View Article : Google Scholar : PubMed/NCBI

Weidle UH, Klostermann S, Eggle D and Krüger A: Interleukin 6/interleukin 6 receptor interaction and its role as a therapeutic target for treatment of cachexia and cancer. Cancer Genomics Proteomics. 7:287–302. 2010.PubMed/NCBI

Zimmers TA, Fishel ML and Bonetto A: STAT3 in the systemic inflammation of cancer cachexia. Semin Cell Dev Biol. 54:28–41. 2016. View Article : Google Scholar : PubMed/NCBI

Cehreli R, Yavuzsen T, Ates H, Akman T, Ellidokuz H and Oztop I: Can inflammatory and nutritional serum markers predict chemotherapy outcomes and survival in advanced stage nonsmall cell lung cancer patients? BioMed Res Int. 2019:16480722019. View Article : Google Scholar : PubMed/NCBI

Johannes CM and Musser ML: Anorexia and the cancer patient. Vet Clin North Am Small Anim Pract. 49:837–854. 2019. View Article : Google Scholar : PubMed/NCBI

Pisetsky DS, Trace SE, Brownley KA, Hamer RM, Zucker NL, Roux-Lombard P, Dayer JM and Bulik CM: The expression of cytokines and chemokines in the blood of patients with severe weight loss from anorexia nervosa: An exploratory study. Cytokine. 69:110–115. 2014. View Article : Google Scholar : PubMed/NCBI

Rochfort KD and Cummins PM: The blood-brain barrier endothelium. A target for pro-inflammatory cytokines. Biochem Soc Trans. 43:702–706. 2015. View Article : Google Scholar : PubMed/NCBI

Dwarkasing JT, Witkamp RF, Boekschoten MV, Ter Laak MC, Heins MS and van Norren K: Increased hypothalamic serotonin turnover in inflammation-induced anorexia. BMC Neurosci. 17:262016. View Article : Google Scholar : PubMed/NCBI

Liu WJ, Wang XD, Wu W and Huang X: Relationship between depression and blood cytokine levels in lung cancer patients. Med Sci (Paris). 34(Focus issue F1): 113–115. 2018. View Article : Google Scholar

Lu YR, Rao YB, Mou YJ, Chen Y, Lou HF, Zhang Y, Zhang DX, Xie HY, Hu LW and Fang P: High concentrations of serum interleukin-6 and interleukin-8 in patients with bipolar disorder. Medicine (Baltimore). 98:e144192019. View Article : Google Scholar

Ju RJ, Stehbens SJ and Haass NK: The role of melanoma cell-stroma interaction in cell motility, invasion, and metastasis. Front Med (Lausanne). 5:3072018. View Article : Google Scholar

Johnson DE, O'Keefe RA and Grandis JR: Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 15:234–248. 2018. View Article : Google Scholar : PubMed/NCBI

Donnelly D III, Aung PP and Jour G: The '-OMICS' facet of melanoma: Heterogeneity of genomic, proteomic and metabolomic biomarkers. Semin Cancer Biol. 59:165–174. 2019. View Article : Google Scholar : PubMed/NCBI